8-K 1 v55931e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 20, 2010
Date of Report (Date of earliest event reported)
(CARDIAC SCIENCE LOGO)
CARDIAC SCIENCE CORPORATION
 
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-51512   94-3300396
         
(State or Other Jurisdiction   (Commission File No.)   (IRS Employer
of Incorporation)       Identification No.)
     
3303 Monte Villa Parkway, Bothell, Washington   98021
 
(Address of Principal Executive Offices)   (Zip Code)
(425) 402-2000
 
(Registrant’s Telephone Number, Including Area Code)
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.
     The annual meeting of stockholders of Cardiac Science Corporation (the “Company”) was held on May 20, 2010 (the “2010 Annual Meeting”). At the 2010 Annual Meeting, the Company’s stockholders re-elected the two directors that were on the ballot and ratified the appointment of KPMG, LLP as the Company’s independent registered public accounting firm. The results of the voting were as follows:
  (1)   Election of two directors nominated by the Company’s board of directors into Class II of the Company’s board of directors to serve until the 2013 Annual Meeting of Stockholders
                         
Nominee   For   Withheld   Abstain or Broker Non-Votes
 
                       
R. Naumann-Etienne
    6,049,491       4,792,661       3,595,849  
Ronald A. Andrews
    10,648,572       193,580       3,595,849  
  (2)   Ratification of the appointment of KPMG, LLP as the Company’s independent registered public accounting firm
                         
    For   Against                      Abstain                    
 
                       
 
     14,347,810         72,711       17,480  

-2-


 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
         
  CARDIAC SCIENCE CORPORATION
 
 
  By:   /s/ Michael K. Matysik    
    Michael K. Matysik   
    Senior Vice President, Chief Financial Officer and Secretary   
 
Dated: May 24, 2010

-3-